March 1, 2019, HemOnc Today 

Sacituzumab govitecan induced durable responses in patients with heavily pretreated metastatic triple-negative breast cancer, according to results of a phase 1/2 single-group trial published in The New England Journal of Medicine. The antibody-drug conjugate also appeared safe among these patients, who achieved better outcomes than those associated with standard chemotherapy for triple-negative disease. 

Read more.